Do Analysts Expect Revance Therapeutics Inc (RVNC) Stock to Rise After It Is Down -4.41% in a Month?

Wall Street is positive on Revance Therapeutics Inc (RVNC). On average, analysts give the stock a Strong Buy rating. The average price target is $28.111, which means analysts expect the stock to gain by 106.09% over the next twelve months. That average ranking earns the stock an Analyst Rating of 63, which is better than 63% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating RVNC a Strong Buy today. Find out what this means to you and get the rest of the rankings on RVNC!

See Full RVNC Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Revance Therapeutics Inc Stock Today?

Revance Therapeutics Inc (RVNC) stock is up 9.47% while the S&P 500 is down -0.39% as of 10:06 AM on Tuesday, Nov 30. RVNC has gained $1.18 from the previous closing price of $12.46 on volume of 287,667 shares. Over the past year the S&P 500 is higher by 28.03% while RVNC is down -43.50%. RVNC lost -$4.48 per share the over the last 12 months. Click Here to get the full Stock Report for Revance Therapeutics Inc stock.